Research on ownership and analyst forecasts provide insight into stock opportunities. Institutional investors hold 49% of Poseida Therapeutics shares, with hedge funds owning 6.2%. Top shareholders have significant stakes, but it's important to consider analyst sentiments and potential future changes.